Abstract：Objective To compare the effect of neoadjuvant chemoradiotherapy (NCRT) and neoadjuvant chemotherapy (NCT) on the survival of patients with esophageal cancer. Methods Clinical data of 275 cases of thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were analyzed retrospectively. The data of treatment and follow-up were complete and analyzable. There were 70 cases in the NCRT group and 205 cases in the NCT group. The survival rate was calculated by Kaplan-Meier method and statistically compared by log-rank test, and multivariate analysis was performed by Cox regression model. Results The median follow-up time was 32(3-84) months. The median survival time and recurrence-free survival time was 42(3-84) months and 30(3-84) months, respectively. The overall 3-and 5-year survival rates were 56.8% and 45.9%,respectively,and the 3-and 5-year recurrence-free survival rates were 45.1% and 38.9%,respectively. The median survival time in the NCRT and NCT groups was 46(7-84) and 40(4-74) months, and the median recurrence-free survival time was 31(3-84) and 28(3-69) months, respectively. The 3-and 5-year overall survival of the two groups were 59.1%,47.1% and 56.3%,47.5%(P=0.515),and the 3-and 5-year recurrence-free survival were 44.5%,40.1% and 47%,39%,respectively. There was no significant difference in the survival between two neoadjuvant therapy modes (P=0.554). Multivariate analysis showed that postoperative pathological TNM staging was an independent factor affecting the prognosis of patients with esophageal cancer (P=0.001). Conclusions The survival results of NCRT are similar to those of NCT. Postoperative pathological staging is an independent survival factor.
Fan Chengcheng,Feng Zhuo,Ge Hong et al. Comparison of survival between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy followed by surgery for esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 890-895.
[1]肖泽芬,杨宗贻,梁军,等. 食管癌根治术后预防性放射治疗的临床价值[J]. 中华肿瘤杂志,2002,24(6):608-611. Xiao ZF, Yang ZY, Liang J, et al. Clinical value of prophalactic radiotherapy after curative resection of esophageal carcinoma[J]. Chin J Onco, 2002, 24(6):608-611. [2]陈俊强,潘建基,陈明强,等. 胸段食管鳞癌淋巴结转移数和区域与术后放疗价值的临床研究[J]. 中华放射肿瘤学杂志,2010,19(2):105-109.DOI: 10. 3760/ cma. j. issn. 1004-4221. 2010. 02. 005. Chen JQ, Pan JJ, Chen MQ, et al. Value of number and distribution of metastatic lymph nodes in postoperative radiotherapy for thoracic esophageal squamous cell carcinoma[J]. Chin J Radiat Oncol,2010,19(2):105-109. DOI:10.3760/cma.j.issn.1004-4221.2010.02.005. [3]Meredith KL,Weber JM,Turaga KK,et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer[J]. Ann Surg Oncol,2010,17(4):1159-1167. DOI:10.1245/s10434-009-0862-1. [4]van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084. DOI:10.1056/NEJMoa1112088. [5]Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol,2011,12(7):681-692. DOI:10.1016/S1470-2045(11)70142-5. [6]Ando N,Kato H,Igaki H,et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol,2012,19(1):68-74. DOI:10.1245/s10434-011-2049-9. [7]Burmeister BH,Thomas JM,Burmeister EA,et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial[J]. Eur J Cancer,2011,47(3):354-360. DOI:10.1016/j.ejca.2010.09.009. [8]Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856. DOI:10.1200/JCO.2008.17.0506. [9]Kumagai K,Rouvelas I,Tsai JA,et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer:a direct and adjusted indirect comparison meta-analysis[J]. Eur J Surg Oncol,2015,41(3):282-294. DOI:10.1016/j.ejso.2014.11.039. [10]Pasquali S,Yim G,Vohra RS,et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma:a network Meta-analysis[J]. Ann Surg,2017,265(3):481-491. DOI:10.1097/SLA.0000000000001905. [11]Deng HY,Wang WP,Wang YC,et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg,2017,51(3):421-431. DOI:10.1093/ejcts/ezw315. [12]Cao XF,He XT,Ji L,et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma[J]. Dis Esophagus,2009,22(6):477-481. DOI:10.1111/j.1442-2050.2008.00910.x. [13]Nygaard K,Hagen S,Hansen HS,et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized,multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer[J]. World J Surg,1992,16(6):1104-1110. [14]Tang H,Tan L,Shen Y,et al. CMISG1701:a multicenter prospective randomized phase Ⅲ clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0)(NCT03001596)[J]. BMC Cancer,2017,17(1):450. DOI:10.1186/s12885-017-3446-7. [15]Larentzakis A,Theodorou D. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0 R0 esophageal cancer[J]. Ann Surg,2014,259(4):e67. DOI:10.1097/SLA.0000000000000364. [16]Yang H,Liu H,Chen Y,et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter,randomized,open-label clinical trial[J]. J Clin Oncol,2018,36(27):2796-2803. DOI:10.1200/JCO.2018.79.1483. [17]Swisher SG,Hofstetter W,Komaki R,et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer[J]. Ann Thorac Surg,2010,90(3):892-899. DOI:10.1016/j.athoracsur.2010.04.061. [18]Hsu HY,Chao YK,Hsieh CH,et al. Postoperative adjuvant therapy improves survival in pathologic nonresponders after neoadjuvant chemoradiation for esophageal squamous cell carcinoma:a propensity-matched analysis[J]. Ann Thorac Surg,2016,102(5):1687-1693. DOI:10.1016/j.athoracsur.2016.05.026. [19]Burt BM,Groth SS,Sada YH,et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer[J]. Ann Surg,2016,266(2):1. DOI:10.1097/SLA.0000000000001954. [20]Glatz T,Bronsert P,Schäfer M,et al. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma:Postoperative chemotherapy has a substantial impact on outcome[J]. Eur J Surg Oncol,2015,41(10):1300-1307. DOI:10.1016/j.ejso.2015.07.010. [21]Brescia AA,Broderick SR,Crabtree TD,et al. Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer[J]. Ann Thorac Surg,2016,101(1):200-210. DOI:10.1016/j.athoracsur.2015.09.001. [22]Sisic L,Blank S,Nienhüser H,et al. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma[J]. Surg Oncol,2017:S0960740417301196. DOI:10.1016/j.suronc.2017.06.001. [23]Crompton P. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer[J]. J Thorac Cardiovasc Surg,2010,139(2):387-394. DOI:10.1016/j.jtcvs.2009.10.003. [24]Pasquali S,Yim G,Vohra RS,et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma:a network Meta-analysis[J]. Ann Surg,2017,265(3):481-491. DOI:10.1097/SLA.0000000000001905.
2019, Vol. 28 
